NIMG-48. USE OF MOBILE LIPIDS AS METABOLIC MARKERS FOR THE ASSESSMENT OF TREATMENT-INDUCED NECROSIS IN A RECURRENT GLIOBLASTOMA PATIENT TREATED WITH A NEW OSCILLATING MAGNETIC FIELD GENERATING DEVICE

The FDA has approved tumor treating fields (Optune) to treat glioblastoma (GBM) and unresectable mesothelioma. Optune uses scalp electrodes to pass a strong alternating electric field through the head, slowing GBM growth. We have recently developed and tested a novel device that uses an oscillating...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Pichumani, Kumar, Ijare, Omkar, Sharpe, Martyn, Nguyen, Lisa, Helekar, Santosh, Baskin, David
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2020
Sujets:
Neuroimaging
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651643/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.661
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires